Year: 2025

Categories : Cancer Ethics and LawTags : Leave a comment

Court Orders Gauteng Health Department to Treat Cancer Patients

On By ModernMedia

Judge rules failure to deal with backlog of patients needing radiation treatment is unconstitutional

By Liezl Human

Photo by Bill Oxford on Unsplash

The Gauteng Department of Health is appealing against a judgment by the Johannesburg High Court ordering it to provide radiation oncology treatment to a backlog of nearly 3000 cancer patients at Charlotte Maxeke Hospital and Steve Biko Hospital.

In April last year, activists from SECTION27, Cancer Alliance and the Treatment Action Campaign (TAC) joined cancer patients to march to the department’s provincial office, demanding that millions of rands set aside for radiation treatment be used.

The matter was then taken to court by the Cancer Alliance, represented by SECTION27, after years of attempts to engage with the department about radiation services. They said in a statement they wanted the court to compel the department to provide treatment to the backlog of cancer patients still waiting.

Some patients have been on the list for nearly three years, while others have died while waiting, according to the judgment by Acting Judge Stephen van Nieuwenhuizen. He noted that “irreparable harm” has occurred and continues to occur in the absence of treatment.

He said the backlog, of mostly Charlotte Maxeke patients, had grown due to a lack of radiation equipment at the hospital and a shortage of staff. This was in spite of an allocation of R784-million over three years, specifically ring-fenced for radiology oncology services. The allocation was also meant to help clear the backlog of patients.

Delays in finalising a tender for these services meant that R250-million was returned to National Treasury at the end of the fiscal year, he said.

The judge found that the provincial department had infringed on the rights of these cancer patients in that a high standard of professional ethics had not been maintained. “Efficient and effective use of resources were not promoted. Services were not provided impartially, fairly, equitably and without bias.”

Judge van Nieuwenhuizen said the provincial health department had done “nothing meaningful” since the money was allocated in March 2023 to actually provide radiation oncology treatment to the cancer patients. “On the other hand, the health and general well-being of cancer patients has significantly deteriorated. There is a clear, imminent and ongoing irreparable harm that cancer patients who are on the backlog list are suffering.”

The judge ruled that the department’s failure to provide radiation services to cancer patients on the backlog list was unconstitutional and unlawful.

He added that the provincial health officials “have conducted themselves as a law unto themselves” and ordered that measures be put in place to ensure officials are “held to account for their constitutionally imposed obligation to provide healthcare services … to cancer patients who are on the backlog list”.

He also ordered that the list of cancer patients still awaiting radiation treatment must be updated within 45 days and that a progress report and long-term plan must be submitted to the court within three months.

Salomé Meyer, director of the Cancer Alliance, told GroundUp the ruling would allow the court to get accurate information on the circumstances of each patient still waiting for treatment.

She said the judgment “confirms that civil society has a role to play to hold the government responsible for what it is supposed to do”.

In a statement on 2 April, the department confirmed that it had filed an application for leave to appeal against the ruling. The department said “there are several substantive grounds of appeal, which if left unchallenged will be greatly prejudicial to the patients undergoing radiation oncology services at the hospitals” and might set an “undesirable” precedent.

Republished from Groundup under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Read the original article.

Categories : Cardiovascular DiseaseTags : Leave a comment

CVD and Obesity: When Protective Lipids Decline, Health Risks Increase

On By ModernMedia
The mesenteric arteries from obese and lean mice, pictured above, supply oxygen and nutrients to the intestines. Immunofluorescence staining revealed that the NOGO-B protein increases in the vascular walls of mice fed a high fat diet compared to mice fed a standard diet. As a result, ceramides decrease in the mesenteric arteries of the obese mice, damaging endothelial cells lining blood vessels. Credit: Annarita Di Lorenzo/Weill Cornell Medicine

New research from Weill Cornell Medicine has uncovered a surprising culprit underlying cardiovascular diseases in obesity and diabetes—not the presence of certain fats, but their suppression. The study, published in Nature Communications, challenges the conventional belief that a type of fat called ceramides accumulates in blood vessels causing inflammation and health risks. Instead, their findings reveal that when ceramides decrease in endothelial cells lining blood vessels, it can be damaging and cause chronic illnesses. Ironically, the findings could ultimately lead to therapies that maintain high levels of these protective lipids in patients with obesity.

Ceramides are found throughout the body and in the endothelium, the thin lining inside blood vessels. These waxy lipids regulate blood vessel tone, dilating or contracting vessels to modulate blood pressure. They also help prevent blood clots, keeping blood flowing easily through the body’s extensive highway of arteries and veins.

“The common assumption in the field was that high levels of ceramides in the endothelium of blood vessels contributed to cardiovascular disease, but this conclusion was extrapolated from in vitro data in cells,” said Dr Annarita Di Lorenzo, professor of pathology and laboratory medicine at Weill Cornell Medicine. “Ours is the first in vivo study that measures the levels of the lipids in the endothelial cells of an animal model. In obese mice fed a high-fat diet, ceramides do not build up—they decrease compared to lean mice.” Also working on this research are co-first authors Dr Onorina L. Manzo, postdoctoral associate and Luisa Rubinelli, both in Dr Di Lorenzo’s lab.

Ceramide to the Rescue

Dr Di Lorenzo and her team discovered the importance of ceramides in blood vessels two years ago. Together with Dr Giuseppe Faraco, assistant professor of neuroscience at Weill Cornell Medicine, they found that decreased levels of ceramides in otherwise healthy mice causes severe blood vessel inflammation in the brain, clot formation and death. Last year, the team reported that ceramide production increases as a protective response in a mouse model of coronary artery disease. Ultimately, when ceramide is broken down by the body it produces a compound called sphingosine-1-phosphate (S1P), which builds up and protects mice against cardiovascular disease. But when this process doesn’t work the mice are left vulnerable.

The researchers also found that two proteins, Nogo-B and ORMDL, decreased the production of ceramides and S1P in obesity. This decrease leads to increased blood pressure, impaired vascular regulation and higher glucose levels—all of which contribute to cardiometabolic conditions that affect the heart (cardiovascular system) and energy processing (metabolism), like diabetes like diabetes, hypertension, coronary artery disease and stroke.

Maintaining Balance

To understand how these different molecules interact, the researchers tested what happens in animal models. Mice with obesity fed a high-fat diet had low levels of ceramides and S1P, but high levels of Nogo-B. These mice showed signs of inflammation, diabetes and high blood pressure.

But what happens if the Nogo-B inhibitor wasn’t present? The researchers knocked out Nogo-B only in the endothelium of blood vessels in a mouse model to find out. “These mice have the same body weight and diabetes as controls, but their blood vessel health is much better,” said Dr. Di Lorenzo. “By knocking out this inhibitor, we preserved vascular health. This also showed that the regulation of ceramide metabolism causes vascular dysfunction and inflammation in obesity.”

The paper suggests that targeting this metabolic pathway could have multiple beneficial effects in the treatment of cardiometabolic diseases related to obesity. “Nogo suppresses biosynthesis of ceramides, so if we can identify a drug that can block Nogo-B, we could restore ceramide levels to a healthy balance and this would fight not only obesity and diabetes, but would directly keep blood vessels functioning properly,” she said.

Source: Weill Cornell Medicine

Categories : IT in HealthcareTags : Leave a comment

Is AI in Medicine Playing Fair?

On By ModernMedia
Photo by Christina Morillo

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may recommend different treatments for the same medical condition based solely on a patient’s socioeconomic and demographic background.  

Their findings, which are detailed in the April 7, 2025 online issue of Nature Medicine, highlight the importance of early detection and intervention to ensure that AI-driven care is safe, effective, and appropriate for all.

As part of their investigation, the researchers stress-tested nine large language models (LLMs) on 1,000 emergency department cases, each replicated with 32 different patient backgrounds, generating more than 1.7 million AI-generated medical recommendations. Despite identical clinical details, the AI models occasionally altered their decisions based on a patient’s socioeconomic and demographic profile, affecting key areas such as triage priority, diagnostic testing, treatment approach, and mental health evaluation. 

“Our research provides a framework for AI assurance, helping developers and health care institutions design fair and reliable AI tools,” says co-senior author Eyal Klang, MD, Chief of Generative-AI in the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai. “By identifying when AI shifts its recommendations based on background rather than medical need, we inform better model training, prompt design, and oversight. Our rigorous validation process tests AI outputs against clinical standards, incorporating expert feedback to refine performance. This proactive approach not only enhances trust in AI-driven care but also helps shape policies for better health care for all.” 

One of the study’s most striking findings was the tendency of some AI models to escalate care recommendations—particularly for mental health evaluations—based on patient demographics rather than medical necessity. In addition, high-income patients were more often recommended advanced diagnostic tests such as CT scans or MRI, while low-income patients were more frequently advised to undergo no further testing. The scale of these inconsistencies underscores the need for stronger oversight, say the researchers. 

While the study provides critical insights, researchers caution that it represents only a snapshot of AI behavior.  Future research will continue to include assurance testing to evaluate how AI models perform in real-world clinical settings and whether different prompting techniques can reduce bias. The team also aims to work with other health care institutions to refine AI tools, ensuring they uphold the highest ethical standards and treat all patients fairly. 

“I am delighted to partner with Mount Sinai on this critical research to ensure AI-driven medicine benefits patients across the globe,” says physician-scientist and first author of the study, Mahmud Omar, MD, who consults with the research team. “As AI becomes more integrated into clinical care, it’s essential to thoroughly evaluate its safety, reliability, and fairness. By identifying where these models may introduce bias, we can work to refine their design, strengthen oversight, and build systems that ensure patients remain at the heart of safe, effective care. This collaboration is an important step toward establishing global best practices for AI assurance in health care.” 

“AI has the power to revolutionize health care, but only if it’s developed and used responsibly,” says co-senior author Girish N. Nadkarni, MD, MPH, Chair of the Windreich Department of Artificial Intelligence and Human Health Director of the Hasso Plattner Institute for Digital Health, and the Irene and Dr. Arthur M. Fishberg Professor of Medicine, at the Icahn School of Medicine at Mount Sinai. “Through collaboration and rigorous validation, we are refining AI tools to uphold the highest ethical standards and ensure appropriate, patient-centered care. By implementing robust assurance protocols, we not only advance technology but also build the trust essential for transformative health care. With proper testing and safeguards, we can ensure these technologies improve care for everyone—not just certain groups.” 

Next, the investigators plan to expand their work by simulating multistep clinical conversations and piloting AI models in hospital settings to measure their real-world impact. They hope their findings will guide the development of policies and best practices for AI assurance in health care, fostering trust in these powerful new tools. 

Source: The Mount Sinai Hospital / Mount Sinai School of Medicine

Categories : Metabolic DisordersTags : Leave a comment

High Muscle Strength Linked to Lower Risk of Type 2 Diabetes

On By ModernMedia
Photo by Jonathan Borba on Unsplash

Researchers from the School of Public Health, LKS Faculty of Medicine of the University of Hong Kong (HKUMed) conducted a large-scale epidemiological study to explore the potential health benefits of high muscle strength in preventing type 2 diabetes (T2D) across varying levels of genetic risk. The study found that higher muscle strength was associated with over 40% lower risk of T2D, regardless of genetic susceptibility to T2D. The study highlights the importance of maintaining or improving muscle strength as a key strategy for preventing T2D. The findings were published in BMC Medicine.

T2D is one of the most common chronic metabolic disorders, and it is associated with an increased risk of various complications, including heart disease, stroke, high blood pressure, and narrowing of blood vessels. It is characterised by hyperglycaemia, due to insulin resistance and impaired insulin secretion. Evidence suggests that around 10% of the global population is affected by T2D, therefore, preventing T2D is a significant global public health concern. T2D can be caused by the interplay between non-modifiable genetic traits and modifiable lifestyle factors. Muscle strength is an important aspect of muscular fitness, and it has been found to be associated with lower risk of various cardiometabolic diseases including T2D. However, it remains unclear whether improving muscle strength should be considered a T2D prevention strategy in individuals with varying levels of genetic susceptibility to T2D, particularly those with high genetic susceptibility to T2D.

The research utilised data of 141 848 white British individuals without baseline T2D from the UK Biobank, an ongoing prospective cohort of over 500 000 UK adults which includes extensive genotype and phenotype information. Muscle strength was assessed in the form of grip strength. Genetic risk of T2D was estimated based on 138 known genetic variants for T2D.

The participants were followed up for more than seven years. During the follow-up period, 4,743 new T2D cases were identified. The findings indicated that, compared with low muscle strength, individuals with high muscle strength was associated with a 44% lower relative risk of developing T2D, even after taking into account T2D genetic risk as well as other risk factors. Moreover, the research team observed evidence of an interaction between muscle strength and genetic susceptibility to T2D, suggesting that muscle strength may play a role in modifying the impact of genetic risk to T2D onset. The findings further revealed that individuals at high genetic risk of T2D but with high muscle strength could have a lower absolute risk of T2D, compared with those at low or medium genetic risk but with low muscle strength.

This groundbreaking study uncovered the first-ever prospective associations between muscle strength, genetic susceptibility to type 2 diabetes, and the risk of developing the disease. ‘The findings emphasise the crucial role of maintaining or enhancing muscle strength as a key strategy for preventing T2D in middle-aged and older adults, regardless of their genetic risk levels and including those at high genetic risk. We believe that these results offer novel insights into the significant impact of higher muscle strength on metabolic health,’ said Dr Wang Mengyao, from the School of Public Health at HKUMed, the first author of this study.

‘This study highlights the significance of Biobank studies in examining the interaction between exposures and genetics in influencing the risk of T2D. Further research utilising ethnic-specific Biobank studies is needed to determine if these findings are applicable to other populations, such as East Asians,’ expressed Professor Ryan Au Yeung, Assistant Professor from the School of Public Health at HKUMed, a co-author of this study.

‘Individuals in middle-to-late life are at increased risk of type 2 diabetes. However, our study has demonstrated the potential roles of high muscle strength in preventing the future risk of developing type 2 diabetes not only in all individuals, but also in individuals with high genetic predisposition to type 2 diabetes. Our study supports the current public health guidelines which suggest that adults should engage in muscle-strengthening activities for at least two days per week from a disease prevention perspective,’ added Professor Youngwon Kim, from the School of Public Health at HKUMed, the corresponding author of the study.

Source: The University of Hong Kong

Categories : Metabolic Disorders NeurologyLeave a comment

Students Lead Breakthrough Study on Diabetes Drugs and Dementia Risk

On By ModernMedia
Source: Pixabay CC0

Two undergraduate medicine students at University of Galway have led a major study examining how cardioprotective glucose-lowering therapies affect the risk of developing dementia.

The research has been published in JAMA Neurology.

The new study involved a systematic review and meta-analysis of 26 clinical trials involving more than 160 000 participants.

The researchers found that while most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, one class of drugs – known as GLP-1 receptor agonists (GLP-1Ras) was linked to a significant reduction.

The study was conducted by medical students Allie Seminer and Alfredi Mulihano, alongside researchers from University of Galway, the HRB Clinical Research Facility Galway and University Hospital Galway.

Key Findings:

  • The research analysed data from 26 randomised controlled trials with a total of 164 531 participants.
  • While glucose-lowering therapies as a whole did not significantly reduce dementia risk, GLP-1 receptor agonists (GLP-1Ras) were linked to a 45% lower risk of dementia.
  • The findings provide crucial insights into the potential for diabetes medications to influence long-term brain health.

Dr Catriona Reddin, senior author, researcher at the University of Galway and Registrar in Geriatric Medicine at HSE West North West, said: “This research represents a significant contribution to our understanding of how some diabetes medications may impact brain health. Diabetes is a known risk factor for dementia, but whether glucose-lowering therapies can help prevent cognitive decline has remained unclear. Our findings suggest that GLP-1 receptor agonists, in particular, may have a protective effect on brain health.”

Professor Martin O’Donnell, Dean of the College of Medicine, Nursing and Health Sciences at University of Galway and Consultant Stroke Physician with HSE West North-West said: “Given the increasing prevalence of both diabetes and dementia, findings from this study have important public health implications for prevention of dementia.

“What makes this study particularly exciting for the College of Medicine, Nursing and Health Sciences at University of Galway, is that it was led by two of our undergraduate medicine students. We place a strong emphasis on research as a core component of our undergraduate medicine programme, ensuring that students have opportunities to engage in high-impact studies that shape global healthcare.”

Allie Seminer, a third year student from New York and co-lead author, said: “Being involved in a study of this scale as an undergraduate has been an incredible experience. What stood out for me was the sense of responsibility – knowing that our work could help shape understanding of a global health issue. It was incredibly motivating to be part of a team working at this level, and it has shown me how research is an essential part of becoming a well-rounded doctor. It highlights how research is not just an add-on to our degree but an essential part of how we learn to advance medical knowledge.”

Alfredi Mulihano, a third year student from Dundalk and co-lead author, said:  “Being part of this study has completely changed how I see my role as a future doctor. It brought together clinical insight, data analysis, and critical thinking in a way that lectures alone cannot. The experience opened my eyes to the impact we can have beyond the bedside – contributing to knowledge that could change how diseases like dementia are prevented.”

Source: University of Galway

Categories : Diet and Nutrition NeurologyTags : Leave a comment

Researchers Discover Natural Compound may Slow ALS and Dementia

On By ModernMedia
Researchers from the University of Missouri have discovered that kaempferol, a natural antioxidant found in certain fruits and vegetables, such as kale, berries and endives, may support nerve cell health and holds promise as a potential treatment for ALS. Photo: Pixabay CC0

A natural compound found in everyday fruits and vegetables may hold the key to protecting nerve cells — and it’s showing promise as a potential treatment for ALS and dementia, according to new research from the University of Missouri.

“It’s exciting to discover a naturally occurring compound that may help people suffering from ALS or dementia,” Smita Saxena, a professor of physical medicine and rehabilitation at the School of Medicine and lead author of the study, said. “We found this compound had a strong impact in terms of maintaining motor and muscle function and reducing muscle atrophy.”

The study, which appears in Acta Neurologica, discovered that kaempferol, a natural antioxidant found in certain fruits and vegetables, such as kale, berries and endives, may support nerve cell health and holds promise as a potential treatment for ALS.

In lab-grown nerve cells from ALS patients, the compound helped the cells produce more energy and eased stress in the protein-processing center of the cell called the endoplasmic reticulum. Additionally, the compound improved overall cell function and slowed nerve cell damage. Researchers found that kaempferol worked by targeting a crucial pathway that helps control energy production and protein management — two functions that are disrupted in individuals with ALS.

“I believe this is one of the first compounds capable of targeting both the endoplasmic reticulum and mitochondria simultaneously,” Saxena said. “By interacting with both of these components within nerve cells, it has the potential to elicit a powerful neuroprotective effect.”

The challenge

The catch? The body doesn’t absorb kaempferol easily, and it could take a large amount to see real benefits in humans. For instance, an individual with ALS would need to consume at least 4.5kg of kale in a day to obtain a beneficial dose.

“Our bodies don’t absorb kaempferol very well from the vegetables we eat,” Saxena said. “Because of this, only a small amount reaches our tissues, limiting how effective it can be. We need to find ways to increase the dose of kaempferol or modify it so it’s absorbed into the bloodstream more easily.”

Another hurdle is getting the compound into the brain. The blood-brain barrier — a tightly locked layer of cells that blocks harmful substances — also makes it harder for larger molecules like kaempferol to pass through.

What’s next?

Despite its challenges, kaempferol remains a promising candidate for treating ALS, especially since it works even after symptoms start. It also shows potential for other neurodegenerative diseases including Alzheimer’s and Parkinson’s.

To make the compound easier for the body to absorb, Saxena’s team at the Roy Blunt NextGen Precision Health building is exploring ways to boost its uptake by neurons. One promising approach involves packaging lipid-based nanoparticles — tiny spherical particles made of fats that are commonly used in drug delivery.

“The idea is to encapsulate kaempferol within lipid-based nanoparticles that are easily absorbed by the neurons,” Saxena said.  “This would target kaempferol to neurons to greatly increase its beneficial effect.”

The team is currently generating the nanoparticles with hopes of testing them by the end of the year.

Source: University of Missouri-Columbia

Categories : Cardiovascular Disease Mental HealthTags : Leave a comment

New Study Investigates Effects of ADHD Medications on the Heart

On By ModernMedia
Photo by Annie Spratt on Unsplash

A new study led by the University of Southampton has found that medications for ADHD have overall small effects on blood pressure and heart rate after weeks or a few months of use.

There have been concerns about the side effects of ADHD medications but the new findings, coupled with other studies, suggest that the benefits of taking these medications outweigh the risks, while highlighting the need for careful monitoring.

The study, published in The Lancet Psychiatry, conducted the largest and most comprehensive analysis of the cardiovascular effects of ADHD medications based on the results of randomised controlled trials – the most rigorous type of clinical study to assess medication effects.

Professor Samuele Cortese, senior lead author of the study from the University of Southampton said: “When it comes to taking any medication, risks and benefits should always be assessed together. We found an overall small increase in blood pressure and pulse for the majority of children taking ADHD medications.

“Other studies show clear benefits in terms of reductions in mortality risk and improvement in academic functions, as well as a small increased risk of hypertension, but not other cardiovascular diseases. Overall, the risk-benefit ratio is reassuring for people taking ADHD medications.”

The study was funded by the National Institute for Health and Care Research (NIHR), within the framework of the NIHR Research Professorships scheme to Professor Samuele Cortese, with Dr Luis Farhat (University of São Paulo, Brazil) as first author and Professor Alexis Revet (University of Toulouse, France) as co-senior author.

It is estimated that attention-deficit/hyperactivity disorder (ADHD) affects around 4 per cent of children in the UK. Of these, around 45 per cent are treated with medication.

The international team of investigators analysed data from 102 randomized controlled trials, including a total of 22,702 participants with ADHD. They used an advanced statistical approach – network meta-analysis – that allowed them to compare the effects of several medications, even when the medications were not directly compared in the trials included in the analysis.

They found that all ADHD medications were generally associated with overall small effects on blood pressure, heart rate, and ECG parameters. With the exception of guanfacine (which leads to decreased blood pressure and heart rate), other medications led to increases in the values of these parameters.

No significant differences were found between stimulants (including methylphenidate and amphetamine) and non-stimulants (atomoxetine and viloxazine) with regard to their effects on blood pressure and heart rate.

“Our findings should inform future clinical guidelines, stressing the need to systematically monitor blood pressure and heart rate, both for stimulants and non-stimulants. This should be particularly relevant for practitioners who might assume that only stimulants have a negative effect on the cardiovascular system,” said Dr Farhat.

The researchers say that those with existing heart conditions should discuss the side effects of ADHD medications with a specialist cardiologist before starting treatment.

Professor Revet added: “Our findings, based on randomised controlled trials that tend to be of short duration due to ethical issues, should be complemented by results from real-world, longer-term studies.”

The research team will now look to see if some groups might be more vulnerable to cardiovascular side effects than others.

NIHR Research Professor Cortese concluded: “While our findings are informative at the group level, that is, on average, we cannot exclude that a subgroup of individuals may have a higher risk of more substantial cardiovascular alterations.

“While it is currently not possible to identify those individuals at higher risk, efforts based on precision medicine approaches will hopefully provide important insights in the future.”

Source: University of Southampton

Categories : Respiratory DiseasesTags : Leave a comment

A Gentle Approach Offers New Hope for Inflammatory Lung Diseases

On By ModernMedia
A collection of immune cells known as a granuloma that results from chronic inflammation in the interstitial lung disease sarcoidosis. White dots indicate the receptor NRP2, which is overexpressed in response to inflammation. Credit: Scripps Research

Pulmonary sarcoidosis is a lung disease characterised by granulomas—tiny clumps of immune cells that form in response to inflammation. It’s the most inflammatory of the interstitial lung diseases (ILDs), a family of conditions that all involve some level of inflammation and fibrosis, or scarring, of the lungs. In the U.S., pulmonary sarcoidosis affects around 200 000 patients. The cause is unknown, and no new treatments have been introduced in the past 70 years. 

In a paper published in Science Translational Medicine, scientists at Scripps Research and aTyr Pharma characterised a protein, HARSWHEP, that can soothe the inflammation associated with sarcoidosis by regulating white blood cells. Reducing inflammation slows the disease’s progression and results in less scarring. A phase 1b/2a clinical trial of efzofitimod, a therapeutic form of HARSWHEP, showed promising results.

“Taken together, these results validate a new way to approach immune regulation in chronic lung disease,” says Paul Schimmel, professor of molecular medicine and chemistry at Scripps Research and the study’s senior author.

The drug’s power lies in its gentle nature. “It’s not a hammer; it’s not overly suppressing the immune system. It’s just nudging the immune system in a certain way,” explains Leslie A. Nangle, Vice President of Research at aTyr Pharma and the paper’s first author. “And if you can quiet the inflammation, you can stop the cycle of ongoing fibrosis.”

HARSWHEP is part of an ancient class of proteins known as aminoacyl-tRNA synthetases (aaRSs). Typically, aaRSs play a key role in protein synthesis. “They’re in every cell in your body. They’re in every organism on the planet,” Nangle says. Over time, new versions known as splice variants have emerged that bind to receptors on the outsides of cells and initiate different events throughout the body.

One such variant, HARSWHEP, entered the picture about 525 million years ago. Nangle and Schimmel screened more than 4,500 receptors and were surprised to find that HARSWHEP will bind only to the receptor neuropilin-2 (NRP2). This receptor is known for its role in development of the lymphatic system—the circulatory system through which immune cells travel—not immune function. But the researchers found that when small, circulating white blood cells known as monocytes enter a tissue in response to inflammation and develop into larger, more specialized white blood cells known as macrophages, those cells start to express high levels of NRP2.

“We had a protein with an unknown function. We had a receptor that was doing something on immune cells that had never been characterized. So we had a couple things we had to match up,” Nangle says.

The team found that HARSWHEP binding to NRP2 physically transforms the macrophage. “It’s creating a new type of macrophage that is less inflammatory and actually helps to resolve inflammation,” Nangle explains.

To characterise HARSWHEP’s mechanism of action, the team administered the protein in mice and rats and found that it reduced lung inflammation and the progression of fibrosis.

In separately published clinical trial data, the team saw a positive impact on patients who were treated with efzofitimod while tapering off of oral corticosteroids. Long-term steroid treatment, currently the first-line option, is associated with significant weight gain and organ damage, and the immunosuppressive effects leave patients vulnerable to infection.

The team also characterised patients’ circulating immune cells before and after efzofitimod treatment. They saw that it reduced key indicators of the inflammation that drives sarcoidosis, such as the concentration of macrophages and other inflammatory immune cells.

While they’re exploring sarcoidosis first, efzofitimod is a potential treatment for many interstitial lung diseases, Nangle explains. The aTyr team plans to explore treating other ILDs and is running a clinical trial now for scleroderma-related ILD.

The work highlights macrophages as a possible target for treating ILDs, and the promise of HARSWHEP could foretell other aaRSs’ therapeutic potential.

Nangle describes this work as moving “from concept to clinic.” Schimmel has worked on aaRSs throughout his tenure at Scripps Research. aTyr Pharma spun out of Schimmel’s lab; his former graduate student Nangle was the company’s first employee upon opening their labs in 2006.

“Original work that happened at Scripps gave rise to the idea that this could be a new class of therapeutic molecules, Nangle says. “We have now moved it all the way to clinical development. It’s a proof of concept for this whole class of molecules and the work Paul has done.”

Source: Scripps Research Institute

Categories : Medical IndustryTags : Leave a comment

Next Biosciences Marks 20 Years of Biotech Innovation

On By ModernMedia
Dr Yvonne Holt, Chief Medical Officer of Next Biosciences (left) with Kim Hulett, Founder and CEO of the company (right) celebrating 20 years of innovation and leadership in stem cell banking, genetic testing and regenerative medicine.

As Next Biosciences celebrates its 20th anniversary, the pioneering South African biotech company reflects on two decades of significant advancements in science and healthcare.

From its roots in medical innovation to its transformative contributions in regenerative medicine, genetic testing and wellness, Next Biosciences has not only shaped the local industry, but also positioned itself as a leader in Africa’s growing biotech sector.

Founded by Kim Hulett, an entrepreneur with a background in finance and technology, and Dr Yvonne Holt, the company has expanded its range of products and services that cover biologics, stem cells, exosomes, genetic testing, longevity and reproductive health.

“The journey of Next Biosciences has been about bringing cutting-edge science and technology to South Africa, and making advancements in health and wellness accessible,” says Dr Holt, Chief Medical Officer at the company. “Every innovation we develop is driven by our mission to positively impact people’s health with science, by transforming lives, improving health outcomes and shaping the future of medicine on the continent.”

With a team of 90, Next Biosciences stands as one of the country’s leading biotech innovators. Women make up 80% of the workforce, with 20% of them being scientists – underscoring the company’s strong commitment to diversity and inclusion. Their lab is accredited by the Association for the Advancement of Blood and Biotherapies (AABB) and ISO 13485 standards, a testament to their excellence in stem cell banking, cord blood services and other biotechnological advancements.

From its beginnings with Netcare, Next Biosciences’ focus on research and development has enabled the company to expand beyond local borders, bringing its innovative healthcare solutions to a wider audience. They now lead initiatives that support regenerative medicine with products like OptiSerum, a revolutionary umbilical cord blood serum for ophthalmic use, and AmnioMatrix, used in a range of medical applications from ophthalmology and wound care to dentistry.

Next Biosciences’ state-of-the-art Netcells storage lab, ensuring the safe preservation of precious stem cells for future medical advancements.

“Biotechnology and regenerative medicine are advancing at an unprecedented pace, offering new possibilities for treating diseases that were once thought incurable. Our focus remains on harnessing these innovations responsibly, ensuring that the latest advancements in cellular therapies, genetic diagnostics and biologics translate into real, life-changing solutions for patients,” says Dr Holt.

The biotechnology landscape has evolved worldwide, and South Africa has not been left behind.

Credit: Global Biotech Indus

The global biotechnology industry is currently valued at $546 billion, growing at approximately 13% per annum. Remarkable advancements have been achieved in genetic research, stem cell therapies and personalised medicine. “The potential for biotechnology over the next decade is extraordinary,” says Hulett, CEO of Next Biosciences. Breakthroughs in regenerative medicine and longevity science are revolutionising healthcare as we know it.”

Next Biosciences’ path hasn’t been without challenges. From navigating regulatory hurdles to sourcing cutting-edge technologies, the company’s growth has been driven by passion, resilience and innovation. As a majority female-led team, the company exemplifies the power of women in science and business, and they have become a beacon for female entrepreneurs looking to make a mark in the science and technology sectors.

“Building a biotech company in SA, with all its complexities, required tenacity and a relentless commitment to our mission. Over the years, we have witnessed our industry evolve and we are proud to have been at the forefront of that change,” says Hulett. “The future holds great promise and we are excited to see what the next 20 years will bring.”

Looking ahead, Next Biosciences aims to expand its footprint in Africa, focusing on reproductive, regenerative and longevity health to empower individuals to invest in their health and live their best lives. With a strong commitment to innovation, accessibility, convenience and sustainability, Next Biosciences plans to integrate cutting-edge biotechnologies, while maintaining a patient-centric approach. By staying at the forefront of the biotech industry, the company is set to strengthen its position as a trusted leader in African healthcare.

Categories : Neurology PaediatricsTags : Leave a comment

Childhood Experiences Shape White Matter with Cognitive Effects Seen Years Later

On By ModernMedia
Photo by Caleb Woods on Unsplash

Mass General Brigham investigators have linked difficult early life experiences with reduced quality and quantity of the white matter communication highways throughout the adolescent brain. This reduced connectivity is also associated with lower performance on cognitive tasks. However, certain social resiliency factors like neighbourhood cohesion and positive parenting may have a protective effect. Results are published in Proceedings of the National Academy of Sciences (PNAS).

White matter are the communication highways that allow the brain networks to carry out the necessary functions for cognition and behaviour. They develop over the course of childhood, and childhood experiences may drive individual differences in how white matter matures. Lead author Sofia Carozza, PhD, and senior author Amar Dhand, MD, PhD, of the Department of Neurology at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, wanted to understand what role this process plays in cognition once children reach adolescence.

“The aspects of white matter that show a relationship with our early life environment are much more pervasive throughout the brain than we’d thought. Instead of being just one or two tracts that are important for cognition, the whole brain is related to the adversities that someone might experience early in life,” said Carozza.

The team studied data from 9082 children (about half of them girls, with an average age of 9.5) collected in the Adolescent Brain Cognitive Development (ABCD) study. This study, funded by the National Institutes of Health and conducted at 21 centres across the U.S., gathered information on brain activity and structure, cognitive abilities, environment, mood and mental health. The researchers looked at several categories of early environmental factors, including prenatal risk factors, interpersonal adversity, household economic deprivation, neighbourhood adversity, and social resiliency factors.

Carozza and Dhand used diffusion imaging scanning of the brain to measure fractional anisotropy (FA)—a way of estimating the integrity of the white matter connections—and streamline count, an estimate of their strength. They then used a computational model to compare how these features of white matter were related to both childhood environmental factors and current cognitive abilities such as language skills and mental arithmetic.

Their analysis revealed widespread differences in white matter connections throughout the brain depending on the children’s early-life environments. In particular, the researchers found lower quality of white matter connections in parts of the brain tied to mental arithmetic and receptive language. These white matter differences accounted for some of the relationship between adverse life experiences in early childhood and lower cognitive performance in adolescence.

“We are all embedded in an environment, and features of that environment such as our relationships, home life, neighbourhood, or material circumstances can shape how our brains and bodies grow, which in turn affects what we can do with them,” said Carozza. “We should work to make sure that more people can have those stable, healthy home lives that the brain expects, especially in childhood.”

The researchers note that their study is based on observational data, which means they cannot draw strong causal conclusions. Brain imaging was also only available at a single timepoint, offering a snapshot but not allowing researchers to track changes over time. Prospective studies—following children over time and collecting brain imaging information at multiple time points—would be needed to more definitively connect adversity and cognitive performance.

Source: Mass General Brigham